INmune was initially published as one of our 7investing Community's New Ideas in August 2024

Discuss INmune Bio in our Community Forum

Background

The following comes directly from our initial Community recommendation. 7investing's opinions may differ from the person(s) who submitted this community research.

Alzheimer's research has struggled for 20 years, mainly focusing on amyloid and tau theories with little success. Recent drugs like Lecanemab and Donanemab from Eli Lilly have only slightly slowed the disease's progression, setting a low bar for new treatments.

New theories suggest neuroinflammation might be the root cause driving amyloid and tau issues. A notable finding is that people with rheumatoid arthritis (RA) have an 800% higher risk of Alzheimer's, but those treated with anti-TNF drugs like Humira or Enbrel have a 60% lower risk.

This raises the question: why aren't these drugs being studied as treatments for Alzheimer's?

InmuneBio's XPro is a next-generation selective anti-TNF inhibitor that targets only the "bad" soluble TNF, leaving the beneficial transmembrane TNF to do its job. This approach is neuroprotective and even helps remyelinate nerves. The company has strong patent protection, significant insider ownership, excellent leadership, and is close to major milestones.

Phase 2 enrollment should end soon, with data readout expected six months later. With a current market cap of $166 million, the potential upside is enormous. The low bar set by existing drugs, combined with promising epidemiology studies, animal studies, and a good safety profile, makes this a compelling investment. Phase 2 readout expected first quarter 2025 will fuel an epic run even with modest results.

Neuroinflammation is not just limited to Alzheimer's. Future targets include Parkinson's disease, treatment-resistant depression, ischemic stroke, multiple sclerosis, and traumatic brain injury.